Engerix-B Vaccine Description
Engerix-B, a Hepatitis B Vaccine, is a noninfectious recombinant DNA hepatitis B vaccine.
It contains purified surface antigen of the virus obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus.
Engerix B is a trademark of the GlaxoSmithKline group of companies.
Engerix-B Vaccine Indication
Engerix-B is a vaccine for immunization against infection caused by all known subtypes of hepatitis B virus.
As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination.
Engerix-B Vaccine Dosage
Engerix-B is administered as an intramuscular injection.
Primary immunization for infants (born of hepatitis B surface antigen [HBsAg]-negative or HBsAg-positive mothers), children (birth through 10 years), and adolescents (aged 11 through 19 years) consist of a series of 3 doses given on a 0-, 1-, and 6-month schedule.
Primary immunization for persons aged 20 years and older consists of a series of 3 doses given on a 0-, 1-, and 6-month schedule.